Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
Historia
24
Películas cinematográficas
16
Música popular
13
Novela estadounidense
12
Jazz
10
Música para órgano
7
Crítica e interpretación
6
Música rock
6
Correspondencia
5
Comedy films
4
Condiciones sociales
4
Diarios íntimos
4
Estados Unidos
4
Música
4
Música vocal (Jazz)
4
Novelistas ingleses
4
Arte
3
Aspectos sociales
3
Bailarines
3
Blues (Música)
3
Christmas music
3
Foreign films
3
Historia y crítica
3
Libros falsos
3
Literatura estadounidense
3
Motetes
3
Música de jazz
3
Operas
3
Songs (High voice) with piano
3
Songs (Medium voice) with piano
3
-
2161por Zizzari, Ilaria Grazia, Veglia, Filippo, Taurino, Federica, Rahimi, Hassan, Quaglino, Elena, Belleudi, Francesca, Riccardo, Federica, Antonilli, Morena, Napoletano, Chiara, Bellati, Filippo, Benedetti-Panici, Pierluigi, Torrisi, Maria Rosaria, Frati, Luigi, Nuti, Marianna, Rughetti, Aurelia“…We designed a recombinant molecule (HER2-Fc) composed of the immunogenic sequence of the human tumor-associated antigen HER2 (aa 364–391) and the Fc domain of a human IgG(1). …”
Publicado 2011
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2162“…PURPOSE: HER-2/neu overexpression is documented in some bladder cancers. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2163por Schrohl, Anne-Sofie, Pedersen, Hans Christian, Jensen, Sussie Steen, Nielsen, Signe Lykke, Brünner, Nils“…AIMS: The availability of specific antibody-based test systems is essential to testing of HER2 protein expression. Here, we mapped epitopes recognized by three pharmacodiagnostic HER2 antibodies and investigated their specificity towards peptides and fusion proteins homologous to the intracellular domains of HER1, HER2, HER3 and HER4. …”
Publicado 2011
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2164por Ettl, T, Baader, K, Stiegler, C, Müller, M, Agaimy, A, Zenk, J, Kühnel, T, Gosau, M, Zeitler, K, Schwarz, S, Brockhoff, G“…Its association with EGFR and HER2 signalling might affect targeted therapy.…”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2165por Harder, J, Ihorst, G, Heinemann, V, Hofheinz, R, Moehler, M, Buechler, P, Kloeppel, G, Röcken, C, Bitzer, M, Boeck, S, Endlicher, E, Reinacher-Schick, A, Schmoor, C, Geissler, M“…In pancreatic cancer, overexpression of the epidermal growth factor receptor 2 (HER2) has been reported in up to 45%. This multicentre phase II study investigated the efficacy and toxicity of the HER2 antibody trastuzumab combined with capecitabine in the patients with pancreatic cancer and HER2 overexpression. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2166por Tsai, Hsiu-Pei, Chen, Shin-Cheh, Chien, Huei-Tzu, Jan, Yi-Yin, Chao, Tzu-Chieh, Chen, Miin-Fu, Hsieh, Ling-Ling“…BACKGROUND: Serum levels of the extracellular domain of HER2/neu (HER2 ECD) have been demonstrated to be associated with clinical outcomes. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2167“…PURPOSE: The aims of our study were to assess the correlation between serum HER2 and clinicopathologic factors, the effect of serum HER2 on survival rate, and the effect of changes in serum HER2 levels between pre- and post-adjuvant chemotherapy on survival rate. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2168“…Through the recent conduct of the ToGA trial, HER2 has shown to be predictive for the treatment with trastuzumab in advanced gastric and gastro-oesophageal cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2169“…PURPOSE: Little information exists about the possible influence of serum HER2/neu on response to chemotherapy. We propose that the assessment of serum HER2/neu in a pretreatment serum sample may be useful in predicting response to neoadjuvant chemotherapy. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2170por Rugo, Hope S., Jo Chien, A., Franco, Sandra X., Stopeck, Alison T., Glencer, Alexa, Lahiri, Soumi, Arbushites, Michael C., Scott, Janet, Park, John W., Hudis, Clifford, Nulsen, Ben, Dickler, Maura N.“…Preclinical data have demonstrated that the combination of antihuman epidermal growth factor receptor-2 (anti-HER2) and antivascular endothelial growth factor (anti-VEGF)—targeted agents has antitumor activity; these data indicate certain patients with HER2-overexpressing breast cancer may derive clinical benefit from this combination. …”
Publicado 2011
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2171por Zielinski, Rafal, Hassan, Moinuddin, Lyakhov, Ilya, Needle, Danielle, Chernomordik, Victor, Garcia-Glaessner, Alejandra, Ardeshirpour, Yasaman, Capala, Jacek, Gandjbakhche, Amir“…Assessment of HER2 expression in vivo would advance development of new HER2-targeted therapeutic agents and, potentially, facilitate choice of the proper treatment strategy offered to the individual patient. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2172por Thiel, Kristina W., Hernandez, Luiza I., Dassie, Justin P., Thiel, William H., Liu, Xiuying, Stockdale, Katie R., Rothman, Alissa M., Hernandez, Frank J., McNamara, James O., Giangrande, Paloma H.“…Trastuzumab, an HER2 antibody-based inhibitor, is currently the leading targeted treatment for HER2(+)-breast cancers. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2173
-
2174por Wishart, G C, Bajdik, C D, Dicks, E, Provenzano, E, Schmidt, M K, Sherman, M, Greenberg, D C, Green, A R, Gelmon, K A, Kosma, V-M, Olson, J E, Beckmann, M W, Winqvist, R, Cross, S S, Severi, G, Huntsman, D, Pylkäs, K, Ellis, I, Nielsen, T O, Giles, G, Blomqvist, C, Fasching, P A, Couch, F J, Rakha, E, Foulkes, W D, Blows, F M, Bégin, L R, van't Veer, L J, Southey, M, Nevanlinna, H, Mannermaa, A, Cox, A, Cheang, M, Baglietto, L, Caldas, C, Garcia-Closas, M, Pharoah, P D P“…The aim of this study was to incorporate the prognostic effect of HER2 status in a new version (Predict+), and to compare its performance with the original Predict and Adjuvant!. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2175por Meng, Le, Hunt, Clayton, Yaglom, Julia A., Gabai, Vladimir L., Sherman, Michael Y.“…Here we investigated the role of Hsp72 in Her2 oncogene-induced neoplastic transformation and tumorigenesis. …”
Publicado 2011
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2176por Ren, Xiu-Rong, Wei, Junping, Lei, Gangjun, Wang, Jiangbo, Lu, Jiuyi, Xia, Wenle, Spector, Neil, Barak, Larry S, Clay, Timothy M, Osada, Takuya, Hamilton, Erika, Blackwell, Kimberly, Hobeika, Amy C, Morse, Michael A, Lyerly, H Kim, Chen, Wei“…INTRODUCTION: Sustained HER2 signaling at the cell surface is an oncogenic mechanism in a significant proportion of breast cancers. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2177por Hu, Yi, Qiao, Chunxia, Lv, Ming, Feng, Jiannan, Yu, Ming, Shen, Beifen, Zhang, Qiuping, Li, Yan“…BACKGROUND: HER2 plays a critical role in the pathogenesis of many cancers and is linked to poor prognosis or cancer metastases. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2178por De Giovanni, C, Nicoletti, G, Landuzzi, L, Romani, F, Croci, S, Palladini, A, Murgo, A, Antognoli, A, Ianzano, M L, Stivani, V, Grosso, V, Iezzi, M, Stramucci, L, Barbieri, E, Lemoli, R M, Nanni, P, Lollini, P-L“…Here, we used HIS mice to study human immune responses against human HER-2-positive cancer cells and their ability to control tumour growth and metastasis. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2179por Lanitis, Evripidis, Dangaj, Denarda, Hagemann, Ian S., Song, De-Gang, Best, Andrew, Sandaltzopoulos, Raphael, Coukos, George, Powell, Daniel J.“…The breadth of HER2 expression by primary human ovarian cancers remains controversial, which questions its suitability as a universal antigen in this malignancy. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2180“…Historically, survival in patients with HER2-positive disease was dictated by the systemic disease course, and what appears to be the central nervous system (CNS) tropism associated with HER2-amplified tumors was not clinically evident. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto